Volume 1 (1). May 2013.

GLIOMAS.ORG NEWSLETTER
_______________________________________________________________________________________________________
GLIOMAS.ORG NEWSLETTERS is a short electronic newsletter periodically released by e-mail as a PDF file to subscribers who want to keep updated on the latest advances on glioma research including but not limited to:
DRUGS & CHEMOTHERAPY NEURORADIOLOGY NEUROIMAGING NEUROSURGERY NEUROPHARMACOLOGY NANOMEDICINE GLIOMA BIOLOGY CLINICAL STUDIES related to the diagnosis, treatment and prognosis of glioma patients. GLIOMAS.ORG. An International Consortium

Mission: To speed research in gliomas.

ACTIVITIES: Research Education Communication Lates updates Patient support Conference Meetings

Each issue of GLIOMAS NEWSLETTERS is the result of a broad screening of the literature in free (e.g. pubmed) or subscription based (e.g. ISI) databases and journals. Interaction with the industry and academic institutions guarantee the early release of relevant information for patients and professionals. The highlights of important studies are briefly summarized in a friendly medical language. Each summary is convenient cited (Reference) at the bottom of the summary to allow anyone interested to quickly find the original source.
www.gliomas.org

New issues of GLIOMAS.ORG NEWSLETTERS are released to subscribers twice a month by e-mail. Old issues are posted online in www.gliomas.org/nl and can be freely distributed by any media. We encourage professionals, clinics and other institutions to print and distribute our newsletter to their staff and patients.
IMAGES IN GLIOMAS RESEARCH

FROM: Yang XJ, Cui W, Gu A, Xu C, Yu SC, Li TT, Cui YH, Zhang X, Bian XW. A novel zebrafish xenotransplantation model for study of glioma stem cell invasion. PLoS One. 2013 Apr 16;8(4):e61801. doi: 10.1371/journal.pone.0061801. _____________________________________________________________________________________________________________________________ Volume 1 (1), May 2013. www.gliomas.org

GLIOMAS.ORG NEWSLETTERS DRUG & CHEMOTHERAPY UPDATES Temozolomide (TMZ) for high grade glioma (HGG) Structure of TMZ TMZ is a novel oral chemotherapy drug that penetrates into the brain and purportedly has a low incidence of adverse events. NANOMEDICINE Nanoparticles for Glioma Treatment

Researchers from France reported in the journal Nanomedicine the increased efficacy of gold nanoparticles (AuNPs) combined with low energy radiations. Rat that received the combined treatment (AuNPs: 50 mg/mL, 15 Gy) showed extended survival compared to animal treated with radiation alone.
REFERENCE : Bobyk Laure, Edouard Magali, Deman Pierre, Vautrin Mathias, Pernet-Gallay Karin, Delaroche Julie, Adam Jean-Francois, Est`eve Francois, Ravanat Jean-Luc, Elleaume Hel`ene, Photoactivation of Gold Nanoparticles for Glioma Treatment, Nanomedicine: Nanotechnology, Biology and Medicine (2013), doi:10.1016/j.nano.2013.04.007

Researchers from the Addenbrookes Hospital in Cambridge, UK by reviewing several databases assessed whether temozolomide has any advantage for treating HGG in either primary or recurrent disease settings. They conluded that TMZ when given in both concomitant and adjuvant phases is an effective primary therapy in GBM compared to radiotherapy alone. It prolongs survival and delays progression without impacting on QoL but it does increase early adverse events. In recurrent GBM, temozolomide compared with standard chemotherapy improves time-to-progression (TTP) and may have benefits on QoL without increasing adverse events but it does not improve overall. In the elderly, temozolomide alone appears comparable to radiotherapy in terms of OS and PFS but with a higher instance of adverse events
Hart MG, Garside R, Rogers G, Stein K, Grant R. Temozolomide for high grade glioma. Cochrane Database Syst Rev. 2013 Apr 30;4:CD007415. doi: 10.1002/14651858.CD007415.pub2.

First combinatorial nano-drug product candidate for Glioma Treatment

Pharmaco-Kinesis Corporation (PKC) today reported development of the first combinatorial nano-drug product candidate, a combination of Temozolomide (Merck &Co.) and Thalidomide (Celgene) nanoparticles to be tested for treatment of gliomas and other cancers.
SOURCE: PHARMACO-KINESIS CORPORATION

NEUROIMAGING Posttreatment evaluation of gliomas

Predicting thromboembolic events during bevacizumab therapy

The D-dimer test is clinically used when there is a suspicion of deep venous thrombosis (DVT), pulmonary embolism (PE) or disseminated intravascular coagulation (DIC). A neurosurgery team from Germany showed that the D-dimer test may have predictive value for gliomas patients receiving bevacizumab. In a cohort of thirty-eight patients that received 428 cycles of bevacizumab venous thromboembolic events (VTE) were observed in five patients (13%). These events were preceded four weeks before the onset of symptoms by D-dimer elevation above 0.865 mg/l. An existing hemiparesis constituted a 27-fold risk elevation for thrombotic complication. The authors concluded that D-Dimer elevation or hemiparesis predict VTE under bevacizumab and chemotherapy, four weeks before the event becomes clinically apparent.
Misch M, Czabanka M, Dengler J, Stoffels M, Auf G, Vajkoczy P, Stockhammer F. D-dimer elevation and paresis predict thromboembolic events during bevacizumab therapy for recurrent malignant glioma. Anticancer Res. 2013 May;33(5):2093-8.

An article by researchers from the Keck School of Medicine, University of Southern California, brings attention to the limitations of conventional contrast-enhanced MR imaging for the posttreatment evaluation of gliomas. These limitations due to recent developments in therapeutic options such as chemoradiation and antiangiogenic agents have challenged the traditional imaging criteria. Although the authors highlight some new recommendations, they also suggest that at present further refinements to glioma response criteria, technical standardization in image acquisition, postprocessing, and interpretation need to be addressed.
Shiroishi MS, Booker MT, Agarwal M, Jain N, Naghi I, Lerner A, Law M. Posttreatment evaluation of central nervous system gliomas. Magn Reson Imaging Clin N Am. 2013 May;21(2):241-68. doi: 10.1016/j.mric.2013.02.004.

GLIOMA BIOLOGY

__________________________________________________________________________________________________________________________ Volume 1 (1), May 2013. www.gliomas.org

GLIOMAS.ORG NEWSLETTERS Glioma Cells Induce Transmigration of Neural Stem Cells across the Blood Brain Barrier II Anticancer Drugs Meeting 22-23 August, 2013 Sotckholm, Sweden

Confirmed Speakers from

US Germany France UK Sweden Egypt Australia Israel Japan Saudi Arabia Mexico Russia

Immunofluorescence localization of claudin-5 and occludin in RBMECs incubated with astrocytes or glioma C6 CM. Arrow, continuous cell border staining; arrowheads, holes appearing at cell borders

In an in vitro model of BBB (rat brain microvascular endothelial cells (RBMECs)) and in nude mice it was demonstrated that Glioma C6 conditioned media (CM) induced a significant transendothelial migration of human neural stem cells in comparison to astrocyte CM. The effect is likely by modulation of the tight junction proteins occludin and claudins. The report was published by a group from the Universidad Autonoma de Mexico.
Daz-Cornguez M, Segovia J, Lpez-Ornelas A, Puerta-Guardo H, Ludert J, Chvez B, Meraz-Cruz N, Gonzlez-Mariscal L. Transmigration of Neural Stem Cells across the Blood Brain Barrier Induced by Glioma Cells. PLoS One. 2013 Apr 5;8(4):e60655. doi: 10.1371/journal.pone.0060655.

and other countries will present their work

Early bird registration deadline May 22, 2013 www.anticancerdrugs.org/2013

_____________________________________________________________________________________________________________________________ Volume 1 (1), May 2013. www.gliomas.org